Lazard Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Lazard Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,350	Closed	-$123K	–	2589
2023 Q1	$123K	Sell	4,350 -353	-8%	-$10.5K	﹤0.01%	1456
2022 Q4	$137K	Buy	4,703 +373	+9%	+$11.9K	﹤0.01%	1403
2022 Q3	$114K	Hold	4,330	–	–	﹤0.01%	1422
2022 Q2	$192K	Buy	4,330 +1,926	+80%	+$88.5K	﹤0.01%	1295
2022 Q1	$118K	Sell	2,404 -1	-0%	-$48	﹤0.01%	1354
2021 Q4	$122K	Buy	2,405 +248	+11%	+$12.8K	﹤0.01%	1388
2021 Q3	$120K	Buy	+2,157	New	+$106K	﹤0.01%	1376
2021 Q1	–	Sell	-1,610	Closed	-$74K	–	2065
2020 Q4	$74K	Buy	1,610 +1,487	+1,209%	+$69.5K	﹤0.01%	1267
2020 Q3	$5K	Sell	123 -1,154	-90%	-$50.5K	﹤0.01%	1546
2020 Q2	$61K	Buy	+1,277	New	+$63.7K	﹤0.01%	1174
2018 Q3	–	Sell	-322,340	Closed	-$24.4M	–	1121
2018 Q2	$24.4M	Sell	322,340 -1,917	-0.6%	-$121K	0.04%	275
2018 Q1	$17.1M	Sell	324,257 -43,240	-12%	-$2.51M	0.03%	330
2017 Q4	$19.6M	Buy	367,497 +15,824	+4%	+$881K	0.03%	309
2017 Q3	$21M	Buy	351,673 +73,391	+26%	+$4.44M	0.04%	278
2017 Q2	$22M	Buy	278,282 +254,007	+1,046%	+$20.8M	0.04%	280
2017 Q1	$2.01M	Sell	24,275 -9,125	-27%	-$678K	﹤0.01%	654
2016 Q4	$2.65M	Hold	33,400	–	–	0.01%	602
2016 Q3	$2.34M	Hold	33,400	–	–	﹤0.01%	611
2016 Q2	$1.29M	Buy	+33,400	New	+$1.39M	﹤0.01%	667

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lazard Asset Management's EGRX Position: Q2 2023 in Review

Lazard Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 4,350 shares — an estimated $123K sold.

Lazard Asset Management first reported a position in EGRX in Q2 2016 and held it in 19 quarters. The position peaked at $24.4M in Q2 2018. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

Lazard Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Lazard Asset Management sold 4,350 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $123K.
Lazard Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 19 quarters.
Lazard Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $24.4M in Q2 2018.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.